Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease.
作者信息
Al-Janabi A, Littlewood Z, Griffiths C E M, Hunter H J A, Chinoy H, Moriarty C, Yiu Z Z N, Warren R B
机构信息
Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, M6 8HD, UK.
National Institute for Health Research, Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UK.
出版信息
Br J Dermatol. 2021 Sep;185(3):646-648. doi: 10.1111/bjd.20479. Epub 2021 Jun 4.
Abstract
摘要
相似文献
1
Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease.接受免疫调节剂治疗免疫介导性炎症疾病的患者对单剂量新冠病毒疫苗接种的抗体反应。
Br J Dermatol. 2021 Sep;185(3):646-648. doi: 10.1111/bjd.20479. Epub 2021 Jun 4.
2
Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.德国一家三级医院的单中心队列研究：炎症性肠病患者对 SARS-CoV-2 疫苗接种的抗体反应。
Dig Dis. 2022;40(6):719-727. doi: 10.1159/000521343. Epub 2021 Dec 10.
3
Analysis of factors involved in the development of humoral response to vaccination against SARS-CoV-2 in patients with rheumatic pathology under biological treatment.分析生物治疗下风湿病理患者对 SARS-CoV-2 疫苗接种产生体液免疫反应的相关因素。
Reumatol Clin (Engl Ed). 2023 Dec;19(10):565-570. doi: 10.1016/j.reumae.2023.05.008. Epub 2023 Nov 25.
4
Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.健康受试者对 mRNA COVID-19 疫苗的抗体反应差异。
Microbiol Spectr. 2021 Sep 3;9(1):e0034121. doi: 10.1128/Spectrum.00341-21. Epub 2021 Aug 4.
5
Antibody response to SARS-CoV-2 vaccination, previous SARS-CoV-2 infection, and change to single-dose vaccination.对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗接种、既往SARS-CoV-2感染的抗体反应以及改为单剂量接种。
J Med Virol. 2021 Dec;93(12):6474. doi: 10.1002/jmv.27263. Epub 2021 Aug 12.
6
Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.抗 SARS-CoV-2 疫苗接种和免疫调节治疗的炎症性肠病患者的抗体反应：前瞻性单中心研究。
Inflamm Bowel Dis. 2022 Oct 3;28(10):1506-1512. doi: 10.1093/ibd/izab301.
7
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.在印度 delta（B.1.617.2）变异株流行期间，ChAdOx1 nCoV-19 疫苗对 SARS-CoV-2 感染的有效性：一项基于病例对照研究的疫苗效力评估和接种后免疫反应的机制研究。
Lancet Infect Dis. 2022 Apr;22(4):473-482. doi: 10.1016/S1473-3099(21)00680-0. Epub 2021 Nov 25.
8
Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry.炎症性肠病患者接种 SARS-CoV-2 疫苗后抗体生成受损：一项泛希腊注册研究的结果。
Inflamm Bowel Dis. 2023 Feb 1;29(2):228-237. doi: 10.1093/ibd/izac068.
9
Antibody Response to SARS-CoV-2 before and after the Third Vaccination in Patients with Inflammatory Bowel Disease.炎症性肠病患者第三次接种疫苗前后对严重急性呼吸综合征冠状病毒2的抗体反应
Dig Dis. 2025;43(1):19-27. doi: 10.1159/000542353. Epub 2024 Nov 30.
10
Time of Day of Vaccination Affects SARS-CoV-2 Antibody Responses in an Observational Study of Health Care Workers.接种时间影响医护人员观察性研究中 SARS-CoV-2 抗体反应。
J Biol Rhythms. 2022 Feb;37(1):124-129. doi: 10.1177/07487304211059315. Epub 2021 Dec 4.
引用本文的文献
1
Immunosuppressants in dermatology on vaccine immunogenicity: a prospective cohort study of pemphigus patients in the pandemic.皮肤科免疫抑制剂对疫苗免疫原性的影响：一项关于大流行期间天疱疮患者的前瞻性队列研究。
Front Immunol. 2024 Nov 22;15:1506962. doi: 10.3389/fimmu.2024.1506962. eCollection 2024.
2
COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases.免疫介导的炎症性疾病中的 COVID-19 疫苗接种与免疫抑制治疗
Vaccines (Basel). 2023 Dec 4;11(12):1813. doi: 10.3390/vaccines11121813.
3
The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-IBD in Seniors.2023年炎症性肠病在加拿大的影响：特殊人群——老年人中的炎症性肠病
J Can Assoc Gastroenterol. 2023 Sep 5;6(Suppl 2):S45-S54. doi: 10.1093/jcag/gwad013. eCollection 2023 Sep.
4
COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study.银屑病患者接受系统治疗时接种 COVID-19 疫苗：一项前瞻性单中心研究。
Front Immunol. 2023 Mar 16;14:1107438. doi: 10.3389/fimmu.2023.1107438. eCollection 2023.
5
The Impact of Immune-Modifying Treatments for Skin Diseases on the Immune Response to COVID-19 Vaccines: a Narrative Review.皮肤病免疫调节治疗对COVID-19疫苗免疫反应的影响：一项叙述性综述。
Curr Dermatol Rep. 2022;11(4):263-288. doi: 10.1007/s13671-022-00376-3. Epub 2022 Oct 25.
6
Equity Considerations in COVID-19 Vaccination Studies of Individuals With Autoimmune Inflammatory Rheumatic Diseases.自身免疫性炎性风湿病患者 COVID-19 疫苗接种研究中的公平性考虑。
Arthritis Care Res (Hoboken). 2023 May;75(5):967-974. doi: 10.1002/acr.25034. Epub 2022 Dec 7.
7
Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics.在接受生物制剂治疗的银屑病患者中，三剂抗SARS-CoV-2 BNT162b2疫苗的免疫原性。
Front Med (Lausanne). 2022 Sep 6;9:961904. doi: 10.3389/fmed.2022.961904. eCollection 2022.
8
Experiences during the COVID-19 Pandemic among People with Inflammatory Arthritis: "Reopening of Society Is Harder than Lock-Down"-A Qualitative Interview Study.炎症性关节炎患者在新冠疫情期间的经历：“社会重启比封锁更艰难”——一项定性访谈研究
Vaccines (Basel). 2022 Jun 21;10(7):982. doi: 10.3390/vaccines10070982.
9
Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis.BNT162b2 mRNA 疫苗加强针在类风湿关节炎患者 SARS-CoV-2 疫苗接种中的作用。
Immunol Res. 2022 Aug;70(4):493-500. doi: 10.1007/s12026-022-09283-y. Epub 2022 May 11.
10
Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response?银屑病关节炎患者的新型冠状病毒2型疫苗接种：治疗会影响免疫反应吗？
Front Med (Lausanne). 2022 Feb 28;9:811829. doi: 10.3389/fmed.2022.811829. eCollection 2022.
本文引用的文献
1
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study.T 细胞和抗体对先前感染和 SARS-CoV-2 阴性的英国医护人员第一剂 BNT162b2 疫苗的反应：一项多中心前瞻性队列研究。
Lancet Microbe. 2022 Jan;3(1):e21-e31. doi: 10.1016/S2666-5247(21)00275-5. Epub 2021 Nov 9.
2
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.在一项单中心队列研究中，慢性炎症性疾病和免疫抑制治疗患者的抗 SARS-CoV-2 mRNA 疫苗的免疫原性和安全性。
Ann Rheum Dis. 2021 Oct;80(10):1306-1311. doi: 10.1136/annrheumdis-2021-220272. Epub 2021 Mar 24.
3
Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.单剂 SARS-CoV-2 mRNA 疫苗后的抗体反应。
N Engl J Med. 2021 May 20;384(20):1959-1961. doi: 10.1056/NEJMc2102051. Epub 2021 Mar 23.
4
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.mRNA 疫苗在实体器官移植受者中的单剂免疫原性。
JAMA. 2021 May 4;325(17):1784-1786. doi: 10.1001/jama.2021.4385.
5
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.既往感染过严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的个体对第一剂BNT162b2的抗体反应。
Lancet. 2021 Mar 20;397(10279):1057-1058. doi: 10.1016/S0140-6736(21)00501-8. Epub 2021 Feb 25.
6
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.在一项 1/2 期临床试验中，单次接种 ChAdOx1 nCoV-19（AZD1222）疫苗诱导的 T 细胞和抗体反应。
Nat Med. 2021 Feb;27(2):270-278. doi: 10.1038/s41591-020-01194-5. Epub 2020 Dec 17.
7
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.两种基于 RNA 的新冠候选疫苗的安全性和免疫原性。
N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14.
Zotero 插件